Animal studies have demonstrated that administration of pharmaceutical KISS1R antagonist suppresses the secretion of reproductive hormones (144), indicating a potential development of therapeutic targets for precocious puberty, endometriosis, some hormone-dependent cancers, and an alternative form of contraception. Here, KISS1R is linked to cancer.